These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34265356)

  • 1. Definitive chemoradiotherapy versus esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma: A retrospective study.
    Jo YY; Yu J; Song KJ; Jang JY; Yoo YJ; Kim SB; Park SR; Kim YH; Kim HR; Kim JH
    Radiother Oncol; 2021 Sep; 162():112-118. PubMed ID: 34265356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.
    Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.
    Sugawara K; Yagi K; Okumura Y; Nishida M; Aikou S; Yamashita H; Yamashita H; Seto Y
    Int J Clin Oncol; 2020 Apr; 25(4):552-560. PubMed ID: 31828451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic findings suggestive of a high risk of non-radical cure after definitive chemoradiotherapy for cT1bN0M0 esophageal squamous cell carcinoma.
    Fukuhara M; Urabe Y; Oka S; Ishibashi K; Konishi H; Mizuno J; Tanaka H; Tsuboi A; Yamashita K; Hiyama Y; Takigawa H; Kotachi T; Yuge R; Hayashi R; Nishibuchi I; Murakami Y; Nagata Y; Tanaka S
    Esophagus; 2023 Jul; 20(3):541-547. PubMed ID: 37027046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Definitive Chemoradiotherapy Versus Radical Esophagectomy in Clinical T1bN0M0 Esophageal Squamous Cell Carcinoma.
    Haneda R; Booka E; Ishii K; Kikuchi H; Hiramatsu Y; Kamiya K; Ogawa H; Yasui H; Takeuchi H; Tsubosa Y
    World J Surg; 2021 Jun; 45(6):1835-1844. PubMed ID: 33620541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcome of esophagectomy and chemoradiotherapy for resectable esophageal squamous cell carcinoma in patients >75 years of age.
    Mayanagi S; Inoue M; Tokizawa K; Fushiki K; Tsushima T; Yokota T; Yamazaki K; Yasui H; Tsubosa Y
    Thorac Cancer; 2024 Jul; 15(21):1656-1664. PubMed ID: 38898742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient selection for salvage surgery after definitive chemoradiotherapy in esophageal squamous cell carcinoma.
    Harada H; Yamashita K; Katada C; Ishiyama H; Soeno T; Washio M; Sakuraya M; Ushiku H; Niihara M; Hosoda K; Hiki N
    Langenbecks Arch Surg; 2020 Sep; 405(6):767-776. PubMed ID: 32671456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of long-term outcomes between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma.
    Zhao H; Koyanagi K; Kato K; Ito Y; Itami J; Igaki H; Tachimori Y
    J Thorac Dis; 2019 Nov; 11(11):4654-4662. PubMed ID: 31903254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esophagectomy versus definitive chemoradiotherapy for patients with clinical stage N0 and pathological stage T1b esophageal squamous cell carcinoma after endoscopic submucosal dissection: study protocol for a multicenter randomized controlled trial (Ad-ESD Trial).
    Yang Y; Su Y; Zhang X; Liu J; Zhang H; Li B; Hua R; Tan L; Chen H; Li Z
    Trials; 2020 Jul; 21(1):603. PubMed ID: 32611448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Comparison Among Neoadjuvant Chemoradiotherapy Followed by Esophagectomy, Definitive Chemoradiotherapy, and Esophagectomy Alone for Esophageal Squamous Cell Carcinoma.
    Chen HS; Lin CH; Wu SC; Wang BY
    Ann Surg Oncol; 2022 Jun; 29(6):3617-3627. PubMed ID: 34994899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma.
    Ma MW; Gao XS; Gu XB; Xie M; Cui M; Zhang M; Liu L; Yin H; Chen LQ
    World J Surg Oncol; 2018 Aug; 16(1):172. PubMed ID: 30119684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II random.
    Qian D; Chen X; Shang X; Wang Y; Tang P; Han D; Jiang H; Chen C; Zhao G; Zhou D; Cao F; Er P; Zhang W; Li X; Zhang T; Zhang B; Guan Y; Wang J; Yuan Z; Yu Z; Wang P; Pang Q
    Radiother Oncol; 2022 Sep; 174():1-7. PubMed ID: 35764191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Yap WK; Chang YC; Hsieh CH; Chao YK; Chen CC; Shih MC; Hung TM
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):689-698. PubMed ID: 29188300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcome After Esophagectomy or Definitive Chemoradiotherapy in Elderly Patients (≥80 Years) With Esophageal Cancer.
    Shimonosono M; Sasaki K; Tsuruda Y; Noda M; Uchikado Y; Arigami T; Matsushita D; Mori S; Kurahara H; Nakajo A; Ohtsuka T
    Anticancer Res; 2022 Aug; 42(8):3953-3961. PubMed ID: 35896243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival after definitive chemoradiotherapy for patients with esophageal cancer: a retrospective cohort study.
    van der Zijden CJ; Bouwman A; Mostert B; Nuyttens JJME; van der Sluis PC; Spaander MCW; Mens JWM; Homs MYV; van Doorn L; Wijnhoven BPL; Lagarde SM
    Dis Esophagus; 2024 Oct; 37(10):. PubMed ID: 38836354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage Esophagectomy After Definitive Chemoradiotherapy for Squamous Cell Esophageal Cancer: A Propensity Score Matching Study in a High-Volume Center.
    Pan J; Liu Z; Yang Y; Li B; Hua R; Guo X; Sun Y; Li C; Li Z
    World J Surg; 2023 Aug; 47(8):2003-2012. PubMed ID: 37097320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The feasibility of post-photodynamic therapy salvage esophagectomy in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Shigeno T; Kajiyama D; Sato K; Fujiwara N; Kinugasa Y; Yano T; Daiko H; Fujita T
    Esophagus; 2023 Oct; 20(4):643-650. PubMed ID: 37391597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy with proton beam for locally advanced esophageal squamous cell carcinoma.
    Ogawa K; Ishikawa H; Hisakura K; Hiroshima Y; Moriwaki T; Yamada T; Yamamoto Y; Akashi Y; Owada Y; Ohara Y; Enomoto T; Furuya K; Doi M; Shimomura O; Takahashi K; Hashimoto S; Sakurai H; Oda T
    Int J Clin Oncol; 2021 Oct; 26(10):1856-1863. PubMed ID: 34241725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.